Drug intelligence / Profile preview

BIND-2206

Development stage: Preclinical
Lead developer: Pfizer
Modality: Small Molecules, Nanoparticles → Drug Delivery Systems
Administration: Oral, Intravenous, Subcutaneous

Overview

BIND-2206 is an Accurin formulation, a nanoparticle drug delivery system, of Merck's AKT inhibitor, MK-2206. Developed by BIND Biosciences in collaboration with Merck, this formulation was shown in preclinical models to enhance tumor exposure, tolerability, and efficacy of the AKT inhibitor in ovarian and prostate cancer.

Targets

AKT1 (Proto-oncogene serine/threonine-protein kinase Akt1)AKT2 (Rac-beta serine/threonine-protein kinase)

Beyond the preview

Go deeper on BIND-2206.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BIND-2206.

Explore the full profile